Cargando…

C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study

BACKGROUND: Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a receptor inhibitor, has previously shown efficacy in an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruchfeld, Annette, Magin, Hasan, Nachman, Patrick, Parikh, Samir, Lafayette, Richard, Potarca, Antonia, Miao, Shichang, Bekker, Pirow
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050557/ https://www.ncbi.nlm.nih.gov/pubmed/35498891 http://dx.doi.org/10.1093/ckj/sfab294

Ejemplares similares

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2020)

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial
por: Merkel, Peter A, et al.
Publicado: (2020)

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis
por: Lundberg, Sigrid, et al.
Publicado: (2017)

Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis
por: Cortazar, Frank B., et al.
Publicado: (2023)

An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
por: Zand, Ladan, et al.
Publicado: (2019)

Avacopan/methylprednisolone/prednisone: Various toxicities: 8 case reports
Publicado: (2022)

Journal Club Review of “Avacopan for the Treatment of ANCA‐Associated Vasculitis”
por: Soulsby, William Daniel
Publicado: (2022)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021)

One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2022)

Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan
por: Alvarez, Luis, et al.
Publicado: (2023)

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023)

Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option
por: Gabilan, Charlotte, et al.
Publicado: (2022)

Avacopan improves patient perspective on steroid-related toxicity effects in a case with ANCA-associated vasculitis
por: Korsten, Peter, et al.
Publicado: (2023)

Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis and Concominant Complement System Activation
por: Hakroush, Samy, et al.
Publicado: (2022)

Response to “Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation”
por: van Leeuwen, Jolijn R., et al.
Publicado: (2022)

The demography of swiping right. An overview of couples who met through dating apps in Switzerland
por: Potarca, Gina
Publicado: (2020)

Sucrose Nephropathy Following IV Immunoglobulin
por: Lakshmanadoss, Umashankar, et al.
Publicado: (2010)

Chapter 10: Immunoglobulin A nephropathy
Publicado: (2012)

Significance of hyperuricemia in immunoglobulin A nephropathy
por: Nasri, Hamid, et al.
Publicado: (2013)

Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy
por: Tanaka, Akihito, et al.
Publicado: (2022)

A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy
por: Han, Sang Youb, et al.
Publicado: (2022)

The complex of immunoglobulin A and uromodulin as a diagnostic marker for immunoglobulin A nephropathy
por: Obara, Takashi, et al.
Publicado: (2012)

Concurrent Drug-Induced Linear Immunoglobulin A Dermatosis and Immunoglobulin A Nephropathy
por: Kim, Ji Seok, et al.
Publicado: (2015)

Idiopathic immunoglobulin A nephropathy in children and adolescents
por: Hogg, Ronald J.
Publicado: (2009)

Kartagener syndrome complicated by immunoglobulin A nephropathy
por: Oka, Kentaro, et al.
Publicado: (2018)

Immunoglobulin A Nephropathy with Erythrocytosis: An Unusual Association
por: Navaradnam, Piratheepan, et al.
Publicado: (2021)

COVID-19 Vaccination in Immunoglobulin A Nephropathy
por: Lim, Cynthia Ciwei, et al.
Publicado: (2021)

pSTAT1 Is Activated during the Progression of IgA Nephropathy
por: Tao, Jianling, et al.
Publicado: (2022)

ANCA Associated Vasculitis Subtypes: Response [Letter]
por: Merkel, Peter A, et al.
Publicado: (2022)

Elevated serum immunoglobulin E level as a marker for progression of immunoglobulin A nephropathy
por: Lee, Ji-Hoon, et al.
Publicado: (2016)

Concurrent Linear Immunoglobulin A Dermatosis, Hashimoto Thyroiditis, and Immunoglobulin A Nephropathy in an Adult
por: Yang, Ji Young, et al.
Publicado: (2017)

A Comparative Study of the Gut Microbiota Associated With Immunoglobulin a Nephropathy and Membranous Nephropathy
por: Dong, Ruijuan, et al.
Publicado: (2020)

The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study
por: Hilderman, Marie, et al.
Publicado: (2020)

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy
por: Bang, Kitae, et al.
Publicado: (2011)

Immunoglobulin A Nephropathy Associated with Plasmodium falciparum Malaria
por: Yoo, Dong Eun, et al.
Publicado: (2012)

Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
por: De Angelis, Maria, et al.
Publicado: (2014)

Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria
por: Iwasaki, Chihiro, et al.
Publicado: (2016)

Hyperuricemia as a marker for progression of immunoglobulin A nephropathy
por: Kim, Su-Ji, et al.
Publicado: (2012)

Immunoglobulin M Nephropathy in a Patient with Wilson’s Disease
por: Ul Abideen, Zain, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j7v7c67iein0qsuhhm8iavnhud